Last reviewed · How we verify
Yangzheng Compound Mixture
Yangzheng Compound Mixture is a Small molecule drug developed by ShuGuang Hospital. It is currently FDA-approved. Also known as: Z10970042（NMPA Approval Number）.
Yangzheng Compound Mixture is a small molecule intervention used to treat sleep disorder in cancer patients, particularly those with Qi-Yin deficiency syndrome undergoing chemotherapy. It is being studied alongside conventional treatment for its potential benefits in this patient population.
At a glance
| Generic name | Yangzheng Compound Mixture |
|---|---|
| Also known as | Z10970042（NMPA Approval Number） |
| Sponsor | ShuGuang Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Yangzheng Compound Mixture CI brief — competitive landscape report
- Yangzheng Compound Mixture updates RSS · CI watch RSS
- ShuGuang Hospital portfolio CI
Frequently asked questions about Yangzheng Compound Mixture
What is Yangzheng Compound Mixture?
Who makes Yangzheng Compound Mixture?
Is Yangzheng Compound Mixture also known as anything else?
What development phase is Yangzheng Compound Mixture in?
Related
- Manufacturer: ShuGuang Hospital — full pipeline
- Also known as: Z10970042（NMPA Approval Number）
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing